Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Glaxosmithkline Pharmaceuticals Ltd share ... DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt.

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Annual ResultsBIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CESTBasel, Switzerland. March 14, 2025, 7am CETBioVersys AG (SIX: BIOV), ...

Hydration Boosters Market. The global hydration boosters market is poised for substantial growth, with a projected valuation ...

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behaviour or pathological gambling - not so ...

Data was also reviewed from two unpublished studies on paroxetine available on the GlaxoSmithKline website. [12] Criteria for inclusion in this review were studies that randomised children to ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Wednesday, 9 April 2025, at 4 PM CEST ...

In 1950, the company synthesised the central nervous system treatment, chlorpromazine, which it later sold to GlaxoSmithKline ... company launched a dedicated website called Sanofi-Aventis TV ...

With Mayne Pharma subject to a $670 million takeover offer, investor attention turns to who might be acquired next. ... Read More The post Biocurious: With Mayne Pharmaceuticals under takeover offer, ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...